Yandex forecasts industrial revolution in 2020sScience & Space September 21, 17:36
Over 3,000 people evacuated from Yandex office over bomb threatSociety & Culture September 21, 17:24
Warsaw’s Soviet Military Cemetery cleared after vandal attackWorld September 21, 17:19
Russian premier slams EU position on Nord Stream 2Business & Economy September 21, 17:13
Tver gunman asks court to reduce his life sentence to 25 years in prisonSociety & Culture September 21, 17:02
Swedish King’s cousin plans to make wine in CrimeaSociety & Culture September 21, 17:01
Over 3,000 people evacuated over bomb threats in Moscow museums, legendary film studioSociety & Culture September 21, 16:39
Putin says Russian economy overcomes recessionBusiness & Economy September 21, 16:14
Police beef up security as migrants flock to Moscow shopping centerSociety & Culture September 21, 15:58
TOKYO, May 22, 2013 /PRNewswire/ -- Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on May 22 the actions that Ranbaxy has taken in recent years to address past conduct under prior management.
Daiichi Sankyo continues to support Ranbaxy in its efforts to address and correct the conduct of the past which led to the investigations by the U.S. Department of Justice ("DOJ") and the U.S. Food and Drug Administration ("USFDA"). These efforts include significant changes to Ranbaxy's management, culture, operations and compliance.
Daiichi Sankyo believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the U.S. DOJ and FDA investigations. Daiichi Sankyo is currently pursuing its available legal remedies and cannot comment further on the subject at this time.
About Daiichi Sankyo Co., Ltd.
Listed: Code No.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges
President and CEO: Joji Nakayama
Noriaki Ishida, Corporate Officer & Vice President Corporate Communications Department Daiichi Sankyo Co., Ltd.